FEDERAL CENTER FOR BIOTECHNOLOGY AND MEDICINE DEVELOPMENT LAUNCHED IN MORDOVIA

A Federal Center for Biotechnology and Medicine Development has officially commenced operations at MRSU. The center’s mission is to develop cutting-edge pharmaceutical products, including biotechnological medicines, addressing the needs of Russia and international markets. A key focus will be on treatments for cancer and autoimmune diseases.

The center was established following a directive from Russian President Vladimir Putin, with the support of Artyom Zdunov, Head of the Republic of Mordovia, and industrial partner Promomed Group, a leading biopharmaceutical innovator.

The total investment for the center amounts to 300 million rubles, with 125.2 million rubles allocated through the federal «Priority 2030» program.

«The launch of the Federal Center for Biotechnology and Medicine Development is a milestone achievement, supported by our President and backed by significant commitments. This project offers new avenues for import substitution and the export of medical services. We believe it will strengthen the university’s standing in the 'Priority 2030' initiative and lead to substantial achievements in both scientific and financial spheres. This marks the beginning of an important journey,» said Artyom Zdunov during the inauguration.

Facilities and Research Capabilities

The initial phase of the center includes laboratories dedicated to microbiology, genetic-engineering biological products, and cellular technologies. These facilities will enable the development and quality control of biotechnological drugs within Russia.

«Leveraging the university’s scientific expertise, we achieved significant progress last year, with 11 clinical trials conducted in collaboration with our industrial partner. This new center will accelerate the introduction of innovative medicines into clinical practice and equip the pharmaceutical sector with uniquely skilled professionals,» noted Dmitry Pyshny, Deputy Minister of Science and Higher Education.

Broader Infrastructure

The center’s infrastructure will incorporate an educational component and a university clinic. Its scope extends beyond biotechnological medicines to encompass research into natural-origin drugs, synthetic pharmaceuticals, and medical devices.

«With seven state-of-the-art laboratories, we are already developing genetic-engineering biological products, analyzing the pharmacokinetics of new drugs, and exploring microbiological potential. We express gratitude to the Ministry of Science and Education, the Head of Mordovia, and our industrial partner for their support. Together, we aim to enhance Russia’s pharmaceutical security,» stated Dmitry Glushko, Rector of N. P. Ogarev Mordovian State University.

Future Plans

This year, the center plans to:

• Accredit existing laboratories,

• Construct a vivarium,

• Continue preclinical and clinical trials of new pharmaceuticals.

These initiatives aim to establish a full-cycle drug production process within Russia, contributing to the country’s pharmaceutical independence.

Strategic Importance

«The opening of this center is a landmark event that aligns with global scientific trends. It will become a hub for businesses, innovative projects, and, most importantly, young scientists who will drive progress in modern science,» commented Stepan Nikolaevich Kalmykov, Vice President of the Russian Academy of Sciences.

International Collaboration

The center has begun partnerships with the food industry to analyze flavor and aroma additives and ensure microbiological food safety. It has also signed agreements for joint research with Mahatma Gandhi University in India and pharmaceutical institutions in China.

«The journey to establish this center arose from the realization that no similar project existed in the country. Previous centers focused on supporting biosimilar production to lower the cost of modern medicines. Today’s breakthrough lies in creating a research hub dedicated to developing entirely new pharmaceuticals,» emphasized Pyotr Bely, Chairman of Promomed Group’s Board of Directors.